Factor Xa inhibitors clinical trials
A class of medicines: the studies that test any of its 12 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Factor Xa Inhibitors.
Get an email when these change. Save the factor xa inhibitors studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
- Letaxaban
- 2
- N-(4-chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidiine-1,2-dicarboxamide
- 1
- Lipoprotein-associated coagulation inhibitor
- 1
- Gw-813893
- 1
Studies by the year they started
605 studies that test it; most in 2021 (43); 1 more planned to start later
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 6 |
| 2004 | 10 |
| 2005 | 3 |
| 2006 | 26 |
| 2007 | 31 |
| 2008 | 16 |
| 2009 | 26 |
| 2010 | 16 |
| 2011 | 12 |
| 2012 | 18 |
| 2013 | 25 |
| 2014 | 28 |
| 2015 | 42 |
| 2016 | 34 |
| 2017 | 38 |
| 2018 | 28 |
| 2019 | 27 |
| 2020 | 42 |
| 2021 | 43 |
| 2022 | 26 |
| 2023 | 27 |
| 2024 | 24 |
| 2025 | 27 |
| 2026 | 28 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 202 · Other 405
Bayer (45) · Bristol-Myers Squibb (26) · Astellas Pharma Inc (21) · Daiichi Sankyo (14) · Assistance Publique - Hôpitaux de Paris (12) · GlaxoSmithKline (11) · Portola Pharmaceuticals (10) · Daiichi Sankyo Co., Ltd. (10)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 607
- To Evaluate The Efficacy And Safety Of Rivaroxaban In Combination With Aspirin Compared With Aspirin Monotherapy In Patients With Stable Coronary Artery Disease (CAD) and High Ischemic RiskNot yet recruitingNot applicableRepublican Specialized Scientific and Practical Medical Center of CardiologyNCT07928583Written as rivaroxaban plus aspirin
- SWITCH: Apixaban vs Vitamin K in HM3RecruitingPhase 3Columbia UniversityNCT07471139Written as Apixaban
- Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic StrokeNot yet recruitingPhase 4Brazilian Clinical Research InstituteNCT06396858Written as Rivaroxaban 2.5 Mg Oral Tablet
- Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple MyelomaRecruitingPhase 4Chen LijuanNCT07907211Written as Rivaroxaban
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ TrialRecruitingPhase 3Sunnybrook Health Sciences CentreNCT07454707Written as Edoxaban 15 mg
- Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki DiseaseRecruitingPhase 4Children's Hospital of Fudan UniversityNCT06978439Written as Rivaroxaban (Xarelto)
- Oral Anticoagulation in Patients With Prior Deep Intracerebral Hemorrhage, Atrial Fibrillation, and Ischemic StrokeNot yet recruitingPhase 4Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07609654Written as Apixaban
- BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral AtherosclerosisRecruitingPhase 4Yonsei UniversityNCT07237308Written as Apixaban
- Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee ArthroplastyRecruitingNot applicableMilitary Hospital of TunisNCT07869615Written as Apixaban
- Vortosiran in Atrial FibrillationNot yet recruitingPhase 2Ribocure Pharmaceuticals ABNCT07870889Written as Apixaban
- HIP Fracture Oral thromboPROphylaxis (Hip PRO Pilot)RecruitingPhase 2University of CalgaryNCT05775965Written as Rivaroxaban 10mg
- Edoxaban Versus Apixaban in Cancer-Associated Venous ThromboembolismNot yet recruitingPhase 4Samsung Medical CenterNCT07852637Written as edoxaban
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial FibrillationRecruitingPhase 4Ottawa Hospital Research InstituteNCT04642430Written as Apixaban
- Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer TreatmentRecruitingPhase 3University of BirminghamNCT07160686Written as Apixaban
- Comparing the Safety and Efficacy of Apixaban and RivaroxabanRecruitingPhase 4VA Office of Research and DevelopmentNCT06953726Written as Apixaban
- Comparison of Aspirin Alone Versus Low-Dose Rivaroxaban Plus Aspirin in Chronic Limb-Threatening IschemiaRecruitingEarly Phase 1King Edward Medical UniversityNCT07832578Written as Low-Dose Rivaroxaban Plus Aspirin,
- Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple MyelomaRecruitingNot applicableCentre Hospitalier Universitaire de Saint EtienneNCT06474182Written as Apixaban
- The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery TrialRecruitingPhase 3Population Health Research InstituteNCT04284839Written as DOAC
- Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis OutcomesRecruitingNot applicableWolfson Medical CenterNCT07820670Written as Rivaroxaban
- Personalizing Thromboprophylaxis for Patients With Peripheral Artery DiseaseRecruitingNot applicableMassachusetts General HospitalNCT07613840Written as Rivaroxaban
See all 607 studies that test one of the factor xa inhibitors →
Codes
What other systems call Factor Xa inhibitors · ClinicalTrials.gg INT008989
- MeSH (NLM) D065427Factor Xa InhibitorsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D065427 | Factor Xa Inhibitors | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.